Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch

US FDA Cleared KRAS G12C Inhibitor For Second-Line NSCLC

Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.

Red paper lungs on wood background
Lumakras is approved for second line or later KRAS G12C-mutated non-small cell lung cancer • Source: Alamy

More from New Products

More from Scrip